Dyadic Reports Q1 2026 Revenue Surge on Cultivated Meat and Biopharma Demand
Event summary
- Q1 2026 revenue rose 182.3% YoY to $1.11M, driven by Proliant agreement and grant revenue
- First purchase orders received for recombinant bovine transferrin from cultivated meat customers
- Commercial launch of AlbuFree™ DX recombinant human albumin with Proliant, sharing profit
- Expanded Fermbox Bio collaboration with first commercialized product: animal-origin-free DNase I
- Cash position at $6.6M as of March 31, 2026, down from $8.6M at year-end 2025
The big picture
Dyadic's Q1 2026 results highlight the growing demand for animal-free recombinant proteins in both cultivated meat and biopharmaceutical sectors. The company's strategic shift toward commercialization is evident in its revenue surge, though its cash position remains a critical watchpoint. The expansion of partnerships, particularly in Asia and Europe, positions Dyadic to capitalize on global trends toward sustainable biomanufacturing.
What we're watching
- Revenue Diversification
- Whether Dyadic can sustain its revenue growth through multiple commercial channels, including cultivated meat and biopharma partnerships.
- Cash Burn Rate
- The pace at which Dyadic's cash reserves deplete as it scales commercial operations and invests in R&D.
- Partnership Execution
- How effectively Dyadic's expanded collaborations with Fermbox Bio and other partners translate into scalable product commercialization.
Related topics